



(11) **EP 1 222 192 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:

Corrected version no 1 (W1 B1)

Bibliography INID code(s) 73

(51) Int Cl.:

C07D 493/04 (2006.01) **A61K 31/34** (2006.01)

A61K 31/36 (2006.01) **A61P 31/12** (2006.01)

(48) Corrigendum issued on:

01.10.2008 Bulletin 2008/40

(86) International application number:

PCT/EP2000/009917

(45) Date of publication and mention
of the grant of the patent:

18.06.2008 Bulletin 2008/25

(87) International publication number:

WO 2001/025240 (12.04.2001 Gazette 2001/15)

(21) Application number: **00966144.8**

(22) Date of filing: **06.10.2000**

(54) **HEXAHYDROFURO-2,3-B FURAN-3-YL-N- 3- γ (1,3-BENZODIOXOL-5-YLSULFONYL)
(ISOBUTYL)AMINO -1-BENZYL-2-HYDROXYPROPYL CARBAMATE AS RETROVIRAL
PROTEASE INHIBITOR**

HEXAHYDROFURO-2,3-B FURAN-3-YL-N- 3- γ (1,3-BENZODIOXOL-5-YLSULFONYL)(ISOBUTYL)
AMINO -1-BENZYL-2-HYDROXYPROPYL CARBAMAT ALS RETROVIRUSPROTEASEHEMMER

HEXAHYDROFURO'2,3-B! FURAN-3-YL-N- 3'(1,3-BENZODIOXOL-5-YLSULFONYL)
(ISOBUTYL) AMINO! -1-BENZYL-2-HYDROXYPROPYL CARBAMATE EN TANT
QU'INHIBITEUR DE PROTEASE RETROVIRALE

(84) Designated Contracting States:

**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE**

Designated Extension States:

LT LV SI

- **WANG, Guangyang**
Gaihersburg, MD 20879 (US)
- **EISSENSTAT, Michael**
Frederick, MD 21702 (US)
- **ERICKSON, John, W.**
Frederick, MD 21703 (US)

(30) Priority: **06.10.1999 US 157850 P**

(43) Date of publication of application:

17.07.2002 Bulletin 2002/29

(74) Representative: **Daelemans, Frank F.R.**

Tibotec N.V.
General De Wittelaan L11 B3
B-2800 Mechelen (BE)

(73) Proprietors:

- **Tibotec Pharmaceuticals Ltd.**
Eastgate
Little Island
Co Cork (IE)
- **THE GOVERNMENT OF THE UNITED STATES OF
AMERICA,**
MD 20852-3804 (US)

(56) References cited:

WO-A-94/05639 **WO-A-95/06030**
WO-A-96/33184 **WO-A-99/67254**
WO-A-99/67417

(72) Inventors:

- **WIGERINCK, Piet, Tom, Bert, Paul**
B-2350 Vosselaar (BE)

- **A. K. GHOSH ET AL.: "Potent HIV protease
inhibitors incorporating high-affinity P2-ligands
and (R)-[(hydroxyethyl)amino]sulfonamide
isostere" BIOORG. MED. CHEM. LETT., vol. 8, no.
6, 1998, pages 687-690, XP002156428**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 1 222 192 B8